Search Prime Grants

2136683

Project Grant

Overview

Grant Description
Sbir Phase I: Integrated Point-of-Care System for Rapid Pathogen Identification in Urinary Tract Infections
Awardee
Grant Program (CFDA)
Place of Performance
Cambridge, Massachusetts 02139-3922 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Nanopath was awarded Project Grant 2136683 worth $255,874 from Directorate for Technology, Innovation and Partnerships in January 2021 with work to be completed primarily in Cambridge Massachusetts United States. The grant has a duration of 1 year and was awarded through assistance program 47.041 Engineering.

SBIR Details

Research Type
SBIR Phase I
Title
SBIR Phase I:Integrated Point-of-Care System for Rapid Pathogen Identification in Urinary Tract Infections
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is improved access to state-of-the-art molecular diagnostic technologies in areas of significant unmet clinical need, such as women’s health. Urinary tract infections (UTIs) are a pressing problem due to the lengthy clinical workflows and large disease incidence. UTIs are one the most common prompts for women to seek health care in the United States and represent a major driver of antibiotic prescriptions. Untreated UTIs can lead to severe complications for the patient, such as systemic bacterial infections. Despite the severity and prevalence of UTIs, diagnostic methodologies remain extremely time-consuming and rely on antiquated culture-based detection, leaving women in pain for up to three days before they are prescribed the appropriate antibiotic therapy. The proposed project will accelerate UTI diagnosis and can be used for other infections as well.This Small Business Innovation Research (SBIR) Phase I project integrates microfluidic methods for cell enrichment with a novel nanostructured substrate for ultrasensitive detection of target nucleic acid sequences. The reader contains software and optical hardware to detect and analyze the test result at the point-of-care. This technology eliminates the need for bacterial culture and nucleic acid amplification through an ultrasensitive detection modality, providing species-level information and genotypic antibiotic resistance data within minutes. The applications of this proposed platform translate beyond UTIs and have utility in other clinical scenarios that currently employ lengthy culture-based steps and molecular testing workflows, such as respiratory infections, bloodstream infections, and prosthetic joint infections.The project goal is to increase sample throughput through microfluidics optimization and automation and to improve sensitivity through novel sensor geometry design.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 21-562

Status
(Complete)

Last Modified 1/5/22

Period of Performance
1/1/22
Start Date
12/31/22
End Date
100% Complete

Funding Split
$255.9K
Federal Obligation
$0.0
Non-Federal Obligation
$255.9K
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to 2136683

Additional Detail

Award ID FAIN
2136683
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Funding Office
490707 DIVISION OF INDUSTRIAL INNOVATION
Awardee UEI
MURFWBMTD7F7
Awardee CAGE
8G6H4
Performance District
07
Senators
Edward Markey
Elizabeth Warren
Representative
Ayanna Pressley

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Research and Related Activities, National Science Foundation (049-0100) General science and basic research Grants, subsidies, and contributions (41.0) $255,874 100%
Modified: 1/5/22